Edit Drescher
- Rheumatology top 1%
- Rheumatoid Arthritis Research and Therapies 22
- Spondyloarthritis Studies and Treatments 7
- Systemic Lupus Erythematosus Research 6
- Hematology top 2%
- Autoimmune and Inflammatory Disorders Research 10
- Immunology top 5%
- Psoriasis: Treatment and Pathogenesis 4
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
- Oncology top 10%
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Lymphoma Diagnosis and Treatment 5
- Co-authors
- Désirée van der HeijdeTerence RooneyScott D. BeattieDouglas SchlichtingPaul EmeryMaria GreenwaldJames Cheng‐Chung WeiDona Fleishaker
- Cited by
- RheumatologyHematologyImmunology
- Journals
- Annals of the Rheumatic Diseases (13 papers)Arthritis & Rheumatology (4 papers)RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (3 papers)
- Partner nations
- United StatesHungaryUnited Kingdom
In The Last Decade
Edit Drescher
34 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 77
- Rheumatology 922
- Hematology 463
- Immunology 486
- Genetics 211
- Oncology 301
Countries citing papers authored by Edit Drescher
This map shows the geographic impact of Edit Drescher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edit Drescher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edit Drescher more than expected).
Fields of papers citing papers by Edit Drescher
This network shows the impact of papers produced by Edit Drescher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edit Drescher. The network helps show where Edit Drescher may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Edit Drescher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 2 | |
| 4 | 2023 | 1 | |
| 5 | 2022 | 8 | |
| 6 | 2021 | 1 | |
| 7 | 2021 | 14 | |
| 8 | 2020 | 13 | |
| 9 | 2018 | 17 | |
| 10 | Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging studybreakdown → | 2017 | 272 |
| 11 | BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) | 2017 | 1 |
| 12 | Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studybreakdown → | 2016 | 301 |
| 13 | Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study | 2016 | 2 |
| 14 | Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study | 2015 | 3 |
| 15 | 2014 | 225 | |
| 16 | 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2013 | 1 |
| 17 | 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. | 2012 | 10 |
| 18 | 2012 | 76 | |
| 19 | 1989 | 3 | |
| 20 | 1988 | 3 |
About Edit Drescher
Edit Drescher is a scholar working on Rheumatology, Hematology and Genetics, having authored 35 papers that have together received 1.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (10 papers), Spondyloarthritis Studies and Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Systemic Lupus Erythematosus Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). The work is most often cited by research in Rheumatology (922 citations), Hematology (463 citations) and Immunology (486 citations). Edit Drescher has collaborated with scholars based in United States, Hungary and United Kingdom. Frequent co-authors include Désirée van der Heijde, Terence Rooney, Scott D. Beattie, Douglas Schlichting, Paul Emery, Maria Greenwald, James Cheng‐Chung Wei, Dona Fleishaker, Thijs Hendrikx and Atul Deodhar. Their work appears in journals such as Annals of the Rheumatic Diseases, Arthritis & Rheumatology, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Rheumatology and Therapy and RMD Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.